Does Mounjaro Work for Weight Loss? Tirzepatide Evidence & Per...

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, tirzepatide demonstrates meaningful weight loss efficacy in clinical research, with participants averaging 20-22% body weight reduction over 68 weeks. However, individual outcomes range from 5% to over 30% loss, reflecting significant person-to-person variation driven by genetic, metabolic, and lifestyle factors.

For patients considering tirzepatide therapy, understanding whether this medication aligns with your unique metabolic profile matters more than general efficacy statistics. PlexusDx supports precision-wellness approaches by connecting clinical evidence with personalized biomarker and genetic context, helping you and your provider make informed decisions.

Tirzepatide's Mechanism: Dual GLP-1 and GIP Receptor Action

Tirzepatide activates both GLP-1 and GIP receptors, distinguishing it from single-receptor GLP-1 agonists. This dual activation enhances insulin secretion, reduces glucagon, and increases satiety signals more potently than monotherapy. The dual mechanism typically produces stronger appetite suppression and metabolic effects.

GIP receptor engagement adds metabolic benefits beyond appetite control, including improved insulin sensitivity and favorable lipid profiles. This explains why some patients experience superior outcomes with tirzepatide compared to single-agent GLP-1 medications. Provider guidance on whether dual-receptor activation aligns with your goals is essential.

Clinical Evidence: What Tirzepatide Outcomes Actually Show

The SURMOUNT phase 3 trials evaluated tirzepatide across three doses (5 mg, 10 mg, 15 mg weekly) in over 5,000 participants with obesity. Results demonstrated dose-dependent weight loss, with the 15 mg dose averaging 22.5% body weight reduction versus 3.1% placebo over 68 weeks. Cardiometabolic benefits included improved blood pressure and lipid profiles.

Trial Outcome	Tirzepatide 15 mg	Tirzepatide 10 mg	Tirzepatide 5 mg	Placebo
Average Body Weight Loss	22.5%	20.9%	16.0%	3.1%
Participants Achieving ≥20% Loss	85%	71%	50%	4%
HbA1c Reduction (Diabetes Subgroup)	-2.0%	-1.9%	-1.5%	-0.1%
Systolic BP Change (mmHg)	-5.5	-4.7	-2.5	-2.1%

Individual Response Variation: Why Outcomes Differ Significantly

Despite consistent average efficacy, approximately 15% of tirzepatide users experience minimal weight loss below 5%, while others achieve 30%+ loss. Variation stems from genetic factors affecting GLP-1 and GIP receptor sensitivity, insulin secretion capacity, baseline metabolism, and adherence patterns. Biomarker assessment provides context for predicting individual trajectories.

Genetic variants in GLP1R, GIPR, FTO, and MC4R genes influence how your body responds to tirzepatide's mechanisms. Patients with favorable genetic predispositions in these pathways may experience more robust appetite suppression and metabolic improvements. A qualified provider should interpret genetic context alongside clinical assessment to inform realistic outcome expectations.

Safety Considerations and Who Should Evaluate Tirzepatide

Tirzepatide is not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe gastroparesis. Common side effects include nausea, vomiting, and diarrhea, typically mild and transient. Serious adverse events are rare but require provider monitoring.

Candidates for tirzepatide include adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities, or type 2 diabetes. Pregnancy, nursing, and certain kidney or cardiovascular conditions require careful evaluation. A comprehensive medical history and baseline labs ensure safe initiation and appropriate dosing under qualified medical supervision.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in peptide-pathway genes (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context for your potential tirzepatide response. These variants reveal predispositions in how your body processes appetite signals and metabolic regulation. Individual variants do not predict exact medication outcomes but can support a more personalized conversation with your provider.

The genetic test may identify whether you carry favorable predispositions in GLP-1 receptor function, GIP signaling, or appetite regulation pathways. This information should be interpreted with a qualified healthcare provider alongside clinical assessment, lifestyle factors, and comorbidities. Genetic context complements—not replaces—medical evaluation and real-world response monitoring.

Understanding your genetic predispositions allows providers to set realistic weight loss goals, anticipate potential side effect tolerance, and determine optimal dosing timing. Combined with compounded tirzepatide options from licensed 503A pharmacies, this precision approach enables more individualized treatment planning and enhanced patient engagement in their wellness journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.